IRB #

STUDY00015206

Title

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib
for the Treatment of Patients with Locally Advanced or Metastatic Solid
Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Principal Investigator

Matthew Taylor

Study Purpose

The study is being done to test any good and bad effects of entrectinib (the study drug) in men and women with advanced cancer with NTRK, ROS1, or ALK gene rearrangements.

Medical Condition(s)

Non-small cell lung cancer (NSCLC)
Colorectal cancer (CRC)
Other solid tumors

Eligibility Criteria

1. Men and women age 18 years or older
2. Locally advanced or metastatic solid tumors
3. NTRK1/2/3, ROS1, or ALK gene rearrangement (shown by genetic test results)
4. Adequate organ function
5. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. After the last dose of the study drug, participants will be contacted by phone every 3 months until the end of the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Ignyta, Inc.

Recruitment End

12/31/2030

Compensation Provided

No


Go Back